The European Society of Cardiology Congress ESC-2025, which this year celebrated its 75th anniversary, is not only a platform for scientific achievements but also for global health policy and cooperation, which once again confirms its exceptional importance in modern cardiology. The congress was attended by approximately 33,000 specialists from 169 countries. Its central theme—”Cardiology Beyond Borders”—focused on global health challenges, equitable access to healthcare, and strengthening preventive strategies. Within the framework of the event, new clinical guidelines and so-called “consensus” documents were presented, as well as the results of many multicenter studies that can significantly change clinical practice.
Among the updated guidelines this year was the “Guidelines for the Management of Valvular Diseases,” where the results of my research performed at Leiden University on the transcatheter treatment of moderate aortic stenosis in patients with heart failure were cited.
Over the past 10 years, I have presented the results of many original scientific studies at the ESC Congress. This year, the topic of my report was the clinical and diagnostic predictors of non-compaction cardiomyopathy in relation to cardiovascular complications. I led and completed this project at the Stanford University Medical Center (Stanford, USA).
Non-compaction cardiomyopathy belongs to congenital heart pathologies and is grouped under unclassified cardiomyopathies. Patients with pathological non-compaction cardiomyopathy may experience heart failure, sudden cardiac death, thromboembolic complications, and ventricular tachycardia. Given this, it was important to determine the clinical and diagnostic parameters (mainly based on cardiac magnetic resonance, CMR, examination) that may have prognostic significance in terms of cardiovascular complications. Based on the results of our research, we developed several risk models that had predictive significance. These models included parameters based on both clinical and non-invasive imaging methods.
The results of the study allow us to pre-select the groups of patients who belong to the group of life-threatening complications and to develop an individualized prevention and treatment strategy for these patients.
Tea Gegenava MD, PhD, Cardiologist, Assistant Professor, Department of Therapy #1, TSMU
